RxDoctor Payments Data

Steven Dobberfuhl, MD

Internal Medicine · Austin, TXNPI 1932105400

Payments from drug & device makers

$17,400in general payments, 2019–2025

Across 576 payments — averaging $30.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$8K
  • GSK$994
  • Novo Nordisk$898
  • AbbVie$801
  • Amgen$701
  • AstraZeneca$600
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$7,00040%
  • Food & beverage$10,21259%
  • Education$1881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,400 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$716,623
Medicare patients
1,032
Services billed
21,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$145,752
JardianceEmpagliflozin96$96,276
EliquisApixaban45$50,995
MyrbetriqMirabegron63$43,664
TrulicityDulaglutide25$31,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$28,937
FarxigaDapagliflozin Propanediol24$18,308
XareltoRivaroxaban12$16,979
JanuviaSitagliptin Phosphate12$14,348
Breo ElliptaFluticasone/Vilanterol23$10,339
Rosuvastatin Calcium284$6,733
Levothyroxine Sodium470$5,764
Lisdexamfetamine Dimesylate15$4,563
Atorvastatin Calcium416$4,434
Ezetimibe65$4,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$898$145,752106 claims
Boehringer IngelheimJardiance$552$96,27696 claims
PfizerEliquis$507$50,99545 claims
Astellas Pharma US IncMyrbetriq$483$43,66463 claims
GSKTrelegy Ellipta, Breo Ellipta$994$39,27668 claims
Lilly USA, LLCTrulicity$7,991$31,28825 claims
AstraZenecaFarxiga$600$18,30824 claims
Johnson & JohnsonXarelto$158$16,97912 claims
MerckJanuvia$104$14,34812 claims
AbbVieSynthroid$801$1,98133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →